BMJ

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs

Osteoarthritis Research Unit, Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada Correspondence to: Professor J Martel-Pelletier, Osteoarthritis ...
BMJ

Quadriceps weakness in knee osteoarthritis: the effect on pain and disability

a Rheumatology Unit, City Hospital, Nottingham NG5 1PB, b Department of Public Health Medicine and Epidemiology, Queens Medical Centre, Nottingham Dr O’Reilly. OBJECTIVES (1) To determine the ...
BMJ

Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis

Correspondence to Dr Mirko Manetti, Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Largo Brambilla 3, Florence 50134, Italy; ...
BMJ

POS1153 PRELIMINARY EVALUATION OF THE SAFETY AND ANALGESIC EFFICACY OF THE TRPV1 AGONIST RTX-GRT7039 IN KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND ...

Background: RTX-GRT7039 (resiniferatoxin; RTX), is a potent and selective agonist of the transient receptor potential vanilloid 1 (TRPV1) being developed for treatment of pain related to knee ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...
BMJ

The squeeze test of MCP joints: a scarcity of scientific data, especially from primary care

1 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 2 Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands Correspondence to A H M van der ...
BMJ

LB0002 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF TILDRAKIZUMAB, A HIGH ...

5 Sun Pharmaceutical Industries, Inc., Princeton, United States of America 6 Cincinnati Rheumatic Disease Study Group, Inc., Cincinnati, United States of America 7 University of Cincinnati College of ...
BMJ

Protein kinase R is highly expressed in dermatomyositis and promotes interferon-beta-induced muscle damage

Objectives Dermatomyositis (DM) has been consistently linked to the type I interferon (IFN-I) pathway. However, the precise pathogenesis remains incompletely elucidated. We aimed to explore potential ...
BMJ

Are patients with systemic lupus erythematosus at increased risk for COVID-19?

Correspondence to Dr Ennio Giulio Favalli, Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano 20122, Lombardia, Italy; ennio.favalli{at}gmail.com The global health emergency generated by the ...
BMJ

FRI0016 R835, A NOVEL IRAK1/4 DUAL INHIBITOR IN CLINICAL DEVELOPMENT, BLOCKS TOLL-LIKE RECEPTOR 4 (TLR4) SIGNALING IN HUMAN AND MOUSE

Background: Toll-Like Receptors (TLR) and Interleukin-1 Receptors (IL-1R) play a critical role in the innate immune response as microbial sensors, providing a bridge between the innate and adaptive ...
BMJ

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA). Methods: All Assessment of SpondyloArthritis international Society ...